Liquidity and Going Concern (Details Narrative) - USD ($) |
6 Months Ended | ||||
---|---|---|---|---|---|
Jul. 31, 2020 |
Apr. 07, 2020 |
Jun. 30, 2020 |
Jul. 28, 2020 |
Dec. 31, 2019 |
|
Accumulated deficit | $ (260,586,081) | $ (192,823,958) | |||
Cystic Fibrosis Program Related Investment Agreement [Member] | Phase 2 b Clinical trial Member | |||||
Consideration payment milestone received | $ 5,000,000 | 5,000,000 | |||
Proceeds from investments on achieving milestones | $ 25,000,000 | ||||
K2 HealthVentures LLC And Ankura Trust Company, LLC [Member] | Loan Agreement [Member] | Subsequent Event [Member] | |||||
Debt face amount | $ 50,000,000 | ||||
Market Offering [Member] | Jefferies LLC [Member] | Maximum [Member] | |||||
Number of common stock shares sold | 75,000,000 |
X | ||||||||||
- Definition Consideration receivable on milestone payments. No definition available.
|
X | ||||||||||
- Definition Proceeds from investments on achieving milestones. No definition available.
|
X | ||||||||||
- Definition Face (par) amount of debt instrument at time of issuance. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition The cumulative amount of the reporting entity's undistributed earnings or deficit. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition The number of shares issued or sold by the subsidiary or equity method investee per stock transaction. No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|